Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
IL-23 Inhibitor (IBD)

Risankizumab

Brand names: Skyrizi

Risankizumab is a monoclonal antibody biologic used to treat moderate-to-severe Crohn's disease and ulcerative colitis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively binds the p19 subunit of interleukin-23, blocking this cytokine's pro-inflammatory signalling in the gut mucosa.

Prescribing in practice

  • Screen for active and latent tuberculosis and other serious infections, including viral hepatitis, before starting, and do not initiate during an active serious infection.
  • Ensure vaccinations are up to date before treatment and avoid live vaccines during therapy.
  • It is given by intravenous induction followed by subcutaneous maintenance, in line with the SPC and NICE-approved pathways.

Monitoring

Monitor for signs and symptoms of infection during treatment and assess clinical and biochemical disease response at review.

Counselling the patient

  • Report fever, persistent cough, or other signs of infection promptly.
  • Keep routine vaccinations current and avoid live vaccines while on treatment.

Evidence & guidelines

NICE recommends risankizumab as an option for moderate-to-severe inflammatory bowel disease where conventional therapy is inadequate.

Reference: Ferrante et al. NEJM 2022 (ADVANCE); Loftus et al. NEJM 2022 (MOTIVATE); NICE TA800 (risankizumab for CD); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways